FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897438922> ?p ?o ?g. }

• W2897438922 abstract "Objective: The aim of this study was to explore the potential involvement of the miR-493-5p/BRCA1 pathway in the anti-cell drug resistance activity of artesunate in lung carcinomas. Method: Two drug-resistant lung carcinoma cell lines, A549 and SBC-3, resistant to cisplatin (DDP) and adriamycin (ADM), respectively, and their parental cell lines (A549 and SBC-3) were used in this study. Cell viability was determined by an MTT assay. The relative expression of miR-493-5p and BRCA1 mRNA was analyzed by quantitative real-time PCR. The protein expression of BRCA1, breast cancer resistance protein (BCRP), and (p)PI3K/AKT was determined by a Western blot. Results: Artesunate attenuated the viability of A549/DDP and SBC-3/ADM cells and suppressed the expression of BCRP, an important multidrug resistance protein in lung carcinoma cells, accompanied by upregulation of miR-493-5p and downregulation of BRCA1. In artesunate-treated A549/DDP and SBC-3/ADM cells, miR-493-5p silencing reversed the anti-cell drug resistance activity of artesunate and resulted in increased cell viability and BRCP expression. Simultaneously, miR-493-5p silencing contributed to BRCA1 upregulation and phosphorylation of PI3K and AKT. As shown by a luciferase reporter gene assay, BRCA1 was a target gene for miR-493-5p, and its expression was negatively regulated by miR-493-5p. miR-493-5p silencing reversed the anticell drug resistance activity of artesunate, and this finding was further supported by a murine tumor-bearing model. Conclusion: The data support the anti-cell drug resistance activity of artesunate in lung carcinoma cells and sheds light on the role of the miR-493-5p/BRCA1 pathway in this process." @default.
• W2897438922 created "2018-10-26" @default.
• W2897438922 creator A5010262106 @default.
• W2897438922 date "2018-06-26" @default.
• W2897438922 modified "2023-09-26" @default.
• W2897438922 title "Artesunate Improves Drug Resistance of Lung Carcinomas Via Regulation of MiR-493-5p" @default.
• W2897438922 cites W1993375705 @default.
• W2897438922 cites W2017297090 @default.
• W2897438922 cites W2020339825 @default.
• W2897438922 cites W2020475978 @default.
• W2897438922 cites W2027187631 @default.
• W2897438922 cites W2031919933 @default.
• W2897438922 cites W2073420121 @default.
• W2897438922 cites W2082739624 @default.
• W2897438922 cites W2104871505 @default.
• W2897438922 cites W2133139077 @default.
• W2897438922 cites W2140979516 @default.
• W2897438922 cites W2162528846 @default.
• W2897438922 cites W2175962889 @default.
• W2897438922 cites W2181657564 @default.
• W2897438922 cites W2302397808 @default.
• W2897438922 cites W2322823151 @default.
• W2897438922 cites W2334478928 @default.
• W2897438922 cites W2401279717 @default.
• W2897438922 cites W2424509516 @default.
• W2897438922 cites W2557013911 @default.
• W2897438922 cites W2559471688 @default.
• W2897438922 cites W2576034792 @default.
• W2897438922 cites W2593768764 @default.
• W2897438922 cites W2595295013 @default.
• W2897438922 doi "https://doi.org/10.31491/csrc.2018.6.015" @default.
• W2897438922 hasPublicationYear "2018" @default.
• W2897438922 type Work @default.
• W2897438922 sameAs 2897438922 @default.
• W2897438922 citedByCount "1" @default.
• W2897438922 countsByYear W28974389222022 @default.
• W2897438922 crossrefType "journal-article" @default.
• W2897438922 hasAuthorship W2897438922A5010262106 @default.
• W2897438922 hasBestOaLocation W28974389221 @default.
• W2897438922 hasConcept C104317684 @default.
• W2897438922 hasConcept C119056186 @default.
• W2897438922 hasConcept C127561419 @default.
• W2897438922 hasConcept C143998085 @default.
• W2897438922 hasConcept C1491633281 @default.
• W2897438922 hasConcept C153911025 @default.
• W2897438922 hasConcept C185592680 @default.
• W2897438922 hasConcept C203014093 @default.
• W2897438922 hasConcept C2776256026 @default.
• W2897438922 hasConcept C2776694085 @default.
• W2897438922 hasConcept C2778048844 @default.
• W2897438922 hasConcept C2778059366 @default.
• W2897438922 hasConcept C2778239845 @default.
• W2897438922 hasConcept C2778371730 @default.
• W2897438922 hasConcept C2780783641 @default.
• W2897438922 hasConcept C29537977 @default.
• W2897438922 hasConcept C502942594 @default.
• W2897438922 hasConcept C53227056 @default.
• W2897438922 hasConcept C54355233 @default.
• W2897438922 hasConcept C55493867 @default.
• W2897438922 hasConcept C62112901 @default.
• W2897438922 hasConcept C62478195 @default.
• W2897438922 hasConcept C71924100 @default.
• W2897438922 hasConcept C75217442 @default.
• W2897438922 hasConcept C81729549 @default.
• W2897438922 hasConcept C81885089 @default.
• W2897438922 hasConcept C86554907 @default.
• W2897438922 hasConcept C86803240 @default.
• W2897438922 hasConcept C95444343 @default.
• W2897438922 hasConcept C98274493 @default.
• W2897438922 hasConceptScore W2897438922C104317684 @default.
• W2897438922 hasConceptScore W2897438922C119056186 @default.
• W2897438922 hasConceptScore W2897438922C127561419 @default.
• W2897438922 hasConceptScore W2897438922C143998085 @default.
• W2897438922 hasConceptScore W2897438922C1491633281 @default.
• W2897438922 hasConceptScore W2897438922C153911025 @default.
• W2897438922 hasConceptScore W2897438922C185592680 @default.
• W2897438922 hasConceptScore W2897438922C203014093 @default.
• W2897438922 hasConceptScore W2897438922C2776256026 @default.
• W2897438922 hasConceptScore W2897438922C2776694085 @default.
• W2897438922 hasConceptScore W2897438922C2778048844 @default.
• W2897438922 hasConceptScore W2897438922C2778059366 @default.
• W2897438922 hasConceptScore W2897438922C2778239845 @default.
• W2897438922 hasConceptScore W2897438922C2778371730 @default.
• W2897438922 hasConceptScore W2897438922C2780783641 @default.
• W2897438922 hasConceptScore W2897438922C29537977 @default.
• W2897438922 hasConceptScore W2897438922C502942594 @default.
• W2897438922 hasConceptScore W2897438922C53227056 @default.
• W2897438922 hasConceptScore W2897438922C54355233 @default.
• W2897438922 hasConceptScore W2897438922C55493867 @default.
• W2897438922 hasConceptScore W2897438922C62112901 @default.
• W2897438922 hasConceptScore W2897438922C62478195 @default.
• W2897438922 hasConceptScore W2897438922C71924100 @default.
• W2897438922 hasConceptScore W2897438922C75217442 @default.
• W2897438922 hasConceptScore W2897438922C81729549 @default.
• W2897438922 hasConceptScore W2897438922C81885089 @default.
• W2897438922 hasConceptScore W2897438922C86554907 @default.
• W2897438922 hasConceptScore W2897438922C86803240 @default.
• W2897438922 hasConceptScore W2897438922C95444343 @default.
• W2897438922 hasConceptScore W2897438922C98274493 @default.
• W2897438922 hasIssue "2" @default.

• next